Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

409
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
409

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Uncovering an alternate pathway of antibiotic resistance in spore-forming bacteria.

Nature communications·2026
Same author

Pathogen species and capsule expression shape opportunistic transfer and the recipient response during plasmid RP4 conjugation.

Communications biology·2026
Same author

Microbes as architects of colonic patterning.

Cell host & microbe·2026
Same author

MLL1 directs gut-associated antibody responses to helminth and bacterial infections.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same author

Acetyl-carnitine improves hyperactivity and learning deficits in <i>KAT6A</i> haploinsufficient mice.

Life science alliance·2026
Same author

Differential gut transmission of IncP plasmid clades involving hypervirulent Klebsiella pneumoniae reveals plasmid-specific ecological adaptation.

Nature communications·2025

Related Experiment Video

Updated: Jan 5, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.3K

Repurposing auranofin as a Clostridioides difficile therapeutic.

Melanie L Hutton1, Havva Pehlivanoglu1, Callum J Vidor1

  • 1Infection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Microbiology, Monash University, Clayton, Victoria, 3800, Australia.

The Journal of Antimicrobial Chemotherapy
|October 24, 2019
PubMed
Summary

Auranofin effectively reduces Clostridioides difficile spores and toxins, improving survival and reducing gut damage in mice. This repurposed drug shows promise for treating C. difficile infections (CDI).

More Related Videos

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment
11:13

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

39.8K
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

13.1K

Related Experiment Videos

Last Updated: Jan 5, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.3K
Culturing and Maintaining Clostridium difficile in an Anaerobic Environment
11:13

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

39.8K
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

13.1K

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Clostridioides difficile infection (CDI) is a major cause of hospital-acquired diarrhea.
  • Current treatments like vancomycin and metronidazole can lead to relapse due to microbiota disruption.
  • Auranofin, an anti-rheumatic drug, has demonstrated in vitro inhibition of C. difficile growth, toxin, and spore production.

Purpose of the Study:

  • To evaluate auranofin's efficacy as a therapeutic agent for CDI.
  • To assess auranofin's impact on C. difficile toxin and spore production in vitro and in vivo.
  • To determine the effect of auranofin on disease outcomes in a mouse model of CDI.

Main Methods:

  • In vitro assays were used to measure auranofin's effect on C. difficile sporulation and toxin production.
  • Mice were treated with auranofin before C. difficile infection and monitored for survival, weight loss, and gut pathology.
  • Fecal analysis was performed to assess in vivo sporulation and toxin levels.

Main Results:

  • Auranofin significantly reduced C. difficile sporulation and toxin production both in vitro and in vivo.
  • Auranofin-treated mice exhibited less weight loss and significantly higher survival rates compared to controls.
  • Significant reduction in toxin-mediated colon and cecum damage was observed in auranofin-treated mice.

Conclusions:

  • Auranofin demonstrates significant potential as a novel therapeutic for C. difficile infections.
  • The drug's ability to inhibit spore and toxin production offers a promising alternative to current treatments.
  • Further investigation into auranofin for CDI treatment is warranted.